Seattle, WA and Oxford, England

 
Sound Pharmaceuticals (SPI) will collaborate with the University of Oxford on a Phase 2 clinical trial to test SPI-1005 for the treatment of bipolar disorder. Bipolar disorder is a psychiatric illness that involves both periods of mania and depression, and affects approximately one percent of adults worldwide. Unfortunately, patients have relatively few treatment options, often involving drugs such as lithium, which has significant side effects. Read More

Sound Pharmaceuticals (SPI) is pleased to announce that it began enrolling a clinical trial to test SPI-1005 in the treatment of Meniere’s Disease (MD). MD or idiopathic endolymphatic hydrops is an inner ear disease that involves episodic vertigo, sensorineural hearing loss, and tinnitus. Read More

Sound Pharmaceuticals is pleased to announce that David Guyer, MD has joined the company as a strategic advisor. Dr. Guyer is an accomplished academic ophthalmologist and an industry leader in the area of vision loss research and retinal drug development. Dr. Guyer is currently the Co-Founder, Chief Executive Officer and Chairman of Ophthotech which he began in 2007. As CEO, Dr. Guyer raised more than $350 million in financing including a $192 million IPO in 2013 and has advanced the lead program into Phase 3 clinical trials.

Read More